Aevi Genomic Medicine Inc. (GNMX)’s Financial Results Comparing With ImmuCell Corporation (NASDAQ:ICCC)

Both Aevi Genomic Medicine Inc. (NASDAQ:GNMX) and ImmuCell Corporation (NASDAQ:ICCC) are Biotechnology companies, competing one another. We will contrast their analyst recommendations, institutional ownership, profitability, risk, dividends, earnings and valuation.

Earnings and Valuation

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Aevi Genomic Medicine Inc. N/A 0.00 N/A -0.50 0.00
ImmuCell Corporation 7 3.74 N/A -0.42 0.00

Table 1 highlights Aevi Genomic Medicine Inc. and ImmuCell Corporation’s top-line revenue, earnings per share (EPS) and valuation.

Profitability

Table 2 provides Aevi Genomic Medicine Inc. and ImmuCell Corporation’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Aevi Genomic Medicine Inc. 0.00% -206.3% -153.6%
ImmuCell Corporation 0.00% -10.2% -7%

Risk and Volatility

Aevi Genomic Medicine Inc. has a beta of 0.67 and its 33.00% less volatile than Standard & Poor’s 500. Competitively, ImmuCell Corporation’s beta is 1.18 which is 18.00% more volatile than Standard & Poor’s 500.

Liquidity

Aevi Genomic Medicine Inc.’s Current Ratio is 2.8 while its Quick Ratio is 2.8. On the competitive side is, ImmuCell Corporation which has a 2.5 Current Ratio and a 1.6 Quick Ratio. Aevi Genomic Medicine Inc. is better positioned to pay off short and long-term obligations compared to ImmuCell Corporation.

Institutional and Insider Ownership

Institutional investors held 19.1% of Aevi Genomic Medicine Inc. shares and 19.1% of ImmuCell Corporation shares. Insiders held 42.43% of Aevi Genomic Medicine Inc. shares. On the other hand, insiders held about 4.9% of ImmuCell Corporation’s shares.

Performance

Here are the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
Aevi Genomic Medicine Inc. -9.88% 2.33% -4.11% -84.21% -86.4% -70.67%
ImmuCell Corporation -3.75% -7.09% -13.6% -25.18% -12.87% -12.58%

For the past year Aevi Genomic Medicine Inc. was more bearish than ImmuCell Corporation.

Summary

ImmuCell Corporation beats on 6 of the 7 factors Aevi Genomic Medicine Inc.

Aevi Genomic Medicine, Inc., a clinical stage biopharmaceutical company, researches and develops novel therapies for pediatric onset and life-altering diseases in the United States. Its lead product candidates include AEVI-001, a glutamatergic neuromodulator, which is in Phase II/III SAGA trial for a genetically-defined subset of adolescent attention deficit hyperactivity disorder patients with specific mutations in their metabotropic glutamate receptor gene network; and AEVI-002, an anti-light monoclonal antibody that is in Phase I clinical trial for use in severe pediatric onset crohnÂ’s disease. The company was formerly known as Medgenics, Inc. and changed its name to Aevi Genomic Medicine, Inc. in December 2016. Aevi Genomic Medicine, Inc. was founded in 2000 and is based in Wayne, Pennsylvania.

ImmuCell Corporation develops, acquires, manufactures, and sells products that enhance animal health and productivity of cows for the dairy and beef industries in the United States and internationally. The company offers First Defense, an orally delivered scours preventive product for calves; Wipe Out Dairy Wipes, which consist of towelettes that are pre-moistened with a Nisin-based formulation to prepare the teat area of a cow in advance of milking; and California Mastitis Test that could be used for bulk tank and individual cow sample monitoring, as well as to determine which quarter of the udder is mastitic. It is also involved in the development of Mast Out, a Nisin-based treatment of subclinical mastitis in lactating dairy cows; and treatments that prevent E. coli K99 and bovine coronavirus, as well as calf scours caused by enteric pathogens. In addition, the company sells various product applications of its First Defense Technology, including a whey protein concentrate for the nutritional and feed supplement markets. ImmuCell Corporation sells its products to distributors and bovine veterinarians, as well as directly to producers. The company was founded in 1982 and is based in Portland, Maine.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.